Back to the Virtual Exhibit Hall



Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical

Company pioneering novel cancer therapies and dedicated to the discovery,

development, and commercialization of novel first-in-class drugs for the

treatment of cancer and other diseases. Karyopharm's Selective Inhibitor

of Nuclear Export (SINE) compounds function by binding with and inhibiting

the nuclear export protein XPO1.

Learn About Our Indications

Prescribing Information

Product Brochure

Product Information Fact Sheet

Patient Profiles


Gregg Stewart

Hematology/Oncology Specialist